SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β₂-agonist use in asthma

Abstract

<b>As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA use from the SABINA programme would indicate a global public health issue.</b>http://bit.ly/33XDrlb